与阿尔茨海默氏症,α-synuclein或血管病理和临床衰退相关的等离子体和CSF蛋白质特征
medRxiv : the preprint server for health sciences
|February 12, 2026
概括
这项研究确定了阿尔茨海默病 (AD),血管病理和α-synucleinopathy的大脑脊髓液中独特的蛋白质特征,揭示了神经退行症的共同标志物,并有助于疾病分类.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生化学
- 蛋白质组学是指蛋白质组学.
背景情况:
- 老年人经常有多种同时发生的大脑病理,包括阿尔茨海默病 (AD),α-synucleinopathy和血管病理.
- 了解这些病理的共同和独特分子特征对于诊断和治疗至关重要.
- 脑脊液 (CSF) 和血的蛋白质分析提供了一种强大的方法来研究这些复杂的相互作用.
研究的目的:
- 识别和描述与AD,α-synucleinopathy和血管病理相关的CSF和血中的差异丰富蛋白质 (DAP).
- 探索不同神经退行性疾病中蛋白质特征的重叠和特异性.
- 研究这些蛋白质标记与认知衰退和大脑缩的关联.
主要方法:
- 使用NULISAseq中枢神经系统疾病小组 (125种蛋白质) 分析来自BioFINDER队伍的脑脊髓液 (n=1,658) 和血 (n=749) 样本.
- 使用线性模型识别与AD相关的DAP (粉样β和tau PET阳性),α-synuclein放大试验 (SAA) 阳性和白质损伤 (WML) 负载.
- 进一步评估与持续PET和WML测量,AD标志性皮质缩和认知衰退 (MMSE) 相关的DAP.
主要成果:
- 确定了84个CSF DAP,具有针对AD (66),血管病理 (55) 和α-synucleinopathy (16) 的独特特征.
- 发现了所有病理学共同的10个DAP (例如,FABP3,UCHL1),表明了一般的神经退行.
- 与AD相关的DAP包括Aβ的质/炎症标记物和tau的突触/神经元标记物;血管病理显示炎症和血管性蛋白质的丰富;DDC与α-synucleinopathy有关.
- 很少有蛋白质预测了所有病理的认知衰退和缩.
- 血分析显示较少的DAP (n=20),但包括已知的AD生物标志物.
结论:
- 在NULISA中,与共享的神经退行性标记者一起,NULISA确定了依赖于阶段的,特定于疾病的,具有有限重叠的CSF生物标记签名.
- 这些发现支持改善神经退行性病理的生物学解释和精细分类.
- 该研究强调了多原子方法在剖析复杂的大脑疾病中的实用性.
更多相关视频
相关概念视频
Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21
Alzheimer Disease ll: Pathophysiology
35
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
35
Dementia l: Introduction
35
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
35


